Influence of di- and tri-phenylethylene estrogen/antiestrogen structure on the mechanisms of protein kinase C inhibition and activation as revealed by a multivariate analysis.
We have performed a systematic study of the interaction of 36 di- and tri-phenylethylene derivatives (DPEs and TPEs) with protein kinase C (PKC). The results were submitted to a multivariate analysis in order to identify the structural features that might be implicated in interference with the activity of three PKC subspecies under three enzyme activation conditions. Four groups of test-compounds, each with common chemical features, could be distinguished clearly. The first group comprised all TPEs substituted with at least one basic dialkylaminoethoxy side-chain. These inhibited type alpha, beta and gamma PKC subspecies activated by Ca2+ and phosphatidylserine (PS) with or without diolein (DO) at micromolar concentrations but did not inhibit protamine sulfate phosphorylation. The other effectors, which all possessed a 1,1-bis-(p-hydroxyphenyl) ethylene moiety, influenced PKC activity at high concentrations (30-200 microM) and could be divided into two groups. One group constituted PKC inhibitors in the TPE series and inhibited PKC activated by Ca2+, PS and DO, as well as protamine sulfate phosphorylation. The other group constituted dual-type inhibitors/activators in the DPE series and stimulated PKC in the presence of Ca2+ and low PS concentrations but inhibited the enzyme in the simultaneous presence of DO. The fourth group of compounds was inactive and had, for the most part, one or two substituents with weak steric hindrance. In agreement with previous data for six lead compounds, this study suggests that, in these chemical series, a basic amino side-chain leads to interaction with phospholipid and the regulatory domain of PKC, whereas a 1,1-bis-(p-hydroxyphenyl) ethylene moiety leads to interaction with the catalytic domain of the enzyme.
Bignon
E
E
INSERM Unité 58, Montpellier, France.
Pons
M
M
Doré
J C
JC
Gilbert
J
J
Ojasoo
T
T
Miquel
J F
JF
Raynaud
J P
JP
Crastes de Paulet
A
A
D000818:Animals; D001665:Binding Sites; D004789:Enzyme Activation; D004965:Estrogen Antagonists / Q000494:pharmacology*; D008958:Models, Molecular; D015999:Multivariate Analysis; D011493:Protein Kinase C / Q000037:antagonists & inhibitors*; D051381:Rats; D013267:Stilbenes / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D013343:Styrenes / Q000494:pharmacology*
D004965:Estrogen Antagonists; D013267:Stilbenes; D013343:Styrenes; C007518:1,1-diphenylethylene; D011493:Protein Kinase C; C037749:triphenylethylene